Combined posttransplant prophylactic IVIg/Anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: A pilot study

Transplantation

Volumn 89, Issue 11, 2010, Pages 1403-1410

  Loupy, Alexandre ^a,b,c   Suberbielle Boissel, Caroline ^c   Zuber, Julien ^b,c   Anglicheau, Dany ^b,c   Timsit, Marc Olivier ^c   Martinez, Frank ^b,c   Thervet, Eric ^b,c   Bruneval, Patrick ^c   Charron, Dominique ^c   Hill, Gary S ^c   Nochy, Dominique ^c   Legendre, Christophe ^b,c  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Anti CD 20; Antibody mediated rejection.; Donor specific antibodies; DSA; IVIg; Kidney transplantation

Indexed keywords

ANTIBODY; BASILIXIMAB; CYCLOSPORIN A; DONOR SPECIFIC ANTIBODY; ENDOBULINE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; CAPILLARITIS; CONTROLLED STUDY; DRUG MEGADOSE; FLUORESCENCE ANALYSIS; GLOMERULITIS; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PILOT STUDY; PLASMAPHERESIS; POSTOPERATIVE CARE; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CALCINEURIN; COMBINED MODALITY THERAPY; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MICROCIRCULATION; MYCOPHENOLIC ACID; PILOT PROJECTS; PLASMAPHERESIS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TISSUE DONORS;

EID: 77953360290     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181da1cc3     Document Type: Article

References (35)

1. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046.
2. Gloor J, Cosio F, Lager DJ, et al. The spectrum of antibody-mediated renal allograft injury: Implications for treatment. Am J Transplant 2008; 8: 1367.
3. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324.
4. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9:2520.
5. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvas-cular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
6. Lefaucheur C, Nochy D, Hill GS, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7: 832.
7. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576.
8. Lerut E, Naesens M, Kuypers DR, et al. Subclinical peritubular capil-laritis at 3 months is associated with chronic rejection at 1 year. Transplantation 2007; 83: 1416.
9. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: Incidence and correlations. Am J Transplant 2009; 9: 1826.
10. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841.
11. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006;6: 346.
12. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758.
13. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
14. Akalin E. Posttransplant immunosuppression in highly sensitized patients. Contrib Nephrol 2009; 162: 27.
15. Anglicheau D, Loupy A, Suberbielle C, et al. Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: A pilot study. Am J Transplant 2007; 7: 1185.
16. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099.
17. Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86: 820.
18. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ("CAN"). Am J Transplant 2007; 7: 518.
19. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.
20. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive cross-matchin living-donor kidney transplantation.Am JTransplant 2003; 3: 1017.
21. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256.
22. Jordan SC, Vo AA, Peng A, et al. Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459.
23. Akalin E, Dinavahi R, Friedlander R, et al. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008; 3: 1160.
24. Gerbase-DeLima M, Campos EF, Tedesco-Silva H, et al. Anti-HLA class II antibodies and chronic allograft nephropathy. Clin Transpl 2006; 201.
25. Campos EF, Tedesco-Silva H, Machado PG, et al. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6: 2316.
26. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclin-ical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561.
27. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7: 1743.
28. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574.
29. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435.
30. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action. Am J Transplant 2006; 6(5 Pt 1): 859.
31. Zarkhin V, Li L, Kambham N, et al. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008; 8: 2607.
32. Becker YT, Becker BN, Pirsch JD, et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996.
33. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747.
34. Fehr T, Rusi B, Fischer A, et al. Rituximab and intravenous immuno-globulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87: 1837.
35. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967.